Tc17 CD8+ T-cells accumulate in murine atherosclerotic lesions, but do not contribute to early atherosclerosis development by Duijn, J. van et al.
Tc17 CD81 T cells accumulate in murine
atherosclerotic lesions, but do not contribute to
early atherosclerosis development
Janine van Duijn , Maaike J.M. de Jong , Naomi Benne , Romain J.T. Leboux ,
Marieke E. van Ooijen , Nicky Kruit, Amanda C. Foks , Wim Jiskoot , Ilze Bot ,
Johan Kuiper, and Bram Slütter *
Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, Room EE1.17, 2333 CC Leiden, The Netherlands
Received 11 June 2020; revised 4 September 2020; editorial decision 23 September 2020; accepted 30 September 2020
Time for primary review: 17 days
Aims CD8þ T cells can differentiate into subpopulations that are characterized by a specific cytokine profile, such as the
Tc17 population that produces interleukin-17. The role of this CD8þ T-cell subset in atherosclerosis remains elu-




Flow cytometry analysis of atherosclerotic lesions from apolipoprotein E-deficient mice revealed a pronounced in-
crease in RORctþCD8þ T cells compared to the spleen, indicating a lesion-specific increase in Tc17 cells. To study
whether and how the Tc17 subset affects atherosclerosis, we performed an adoptive transfer of Tc17 cells or
undifferentiated Tc0 cells into CD8-/- low-density lipoprotein receptor-deficient mice fed a Western-type diet.
Using flow cytometry, we showed that Tc17 cells retained a high level of interleukin-17A production in vivo.
Moreover, Tc17 cells produced lower levels of interferon-c than their Tc0 counterparts. Analysis of the aortic root
revealed that the transfer of Tc17 cells did not increase atherosclerotic lesion size, in contrast to Tc0-treated mice.
....................................................................................................................................................................................................
Conclusion These findings demonstrate a lesion-localized increase in Tc17 cells in an atherosclerotic mouse model. Tc17 cells
appeared to be non-atherogenic, in contrast to their Tc0 counterpart.
                                                                                                                                                                                                                   
* Corresponding author. Tel: þ31 71 527 6208; fax: þ31 71 5276032, E-mail: b.a.slutter@lacdr.leidenuniv.nl
VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which per-


























































Keywords CD8 T-cell • Atherosclerosis • IL-17 • IFN-c
1. Introduction
Atherosclerosis, the most frequent underlying pathology of cardiovascu-
lar disease, is characterized by both the buildup of cholesterol as well as
chronic inflammation within the wall of large- and medium-sized arteries.
T cells are observed in both early and advanced atherosclerotic lesions1
and have been shown to contribute to lesion initiation and progres-
sion.2–4 Different subsets of CD4þ helper-T cells have been extensively
described and studied in the context of atherosclerosis.5 A pro-
atherogenic function is ascribed to the interferon-c (IFN-c)-producing T
helper 1 (Th1) subset,6,7 whereas the interleukin (IL)-10-producing regu-
latory T cells (Tregs) are atheroprotective.8,9 The role of the Th2 subset,
characterized by the production of IL-4 and IL-5, is more controversial.
Whereas the signature Th2 cytokines IL-4, IL-5, and IL-33 are reported
to inhibit atherosclerosis development,2,10,11 reduced Th2 responses
and IL-4 deficiency were also reported to decrease lesion formation,12–
14 suggesting a pro-atherogenic role for Th2 cells as well. Finally, the IL-
17-producing Th17 subset is known to drive autoimmunity and athero-
genesis via activation of the endothelium, increasing pro-inflammatory
cytokine production, and contributing to macrophage recruitment.15–17
In contrast, loss of suppressor of cytokine signalling (SOCS) 3 in T cells,
resulting in increased IL-17 and IL-10 production, reduces atheroscle-
rotic lesion development.18 This effect is mediated via the induction of
an anti-inflammatory macrophage phenotype and a reduction in vascular
inflammation. Interestingly, treatment with recombinant IL-17 resulted in
reduced expression of vascular cell adhesion molecule-1 (VCAM-1) as
well as reduced T-cell infiltration in the lesions, suggesting the
aforementioned atheroprotective effects of SOCS3 knockout are at
least in part mediated via IL-17.
In a similar vein to their CD4þ T-cell counterparts, CD8þ T cells can
be categorized into subsets based on their cytokine production. Upon
activation of CD8þ T cells, cytokines released by antigen-presenting cells
(APCs) can influence the differentiation of the CD8þ T cells into differ-
ent subsets. The cytokines IL-2 and IL-12 drive CD8þ T cells towards a
Tc1 phenotype through the induction of the transcription factor T-box-
containing protein expressed in T cells (T-bet).19,20 Tc1 cells are known
for their cytotoxic function and expression of effector molecules, such
as granzymes, perforin, IFN-c, and TNF-a.21,22 These cells confer protec-
tion against intracellular infections23,24 as well as cancer.25 Alternatively,
the release of IL-4 by the APCs polarizes CD8þ T cells towards a Tc2
phenotype.26 These cells express the transcription factor GATA3 and
are characterized by the production of the cytokines IL-4, IL-5, and IL-
13.21,26–28 This cell type is known to propagate allergic reactions and
contribute to autoimmune disorders, such as arthritis.29–31 Finally, expo-
sure to the cytokines IL-6, IL-21, and TGF-b drives CD8þ T cells to dif-
ferentiate towards a Tc17 phenotype, by inducing the expression of the
transcription factors RAR-related orphan nuclear receptor ct (RORct)
and IFN regulatory factor 4.32,33 Tc17 cells are characterized by their
production of IL-17 and have been shown to play a pro-inflammatory
role in several autoimmune disorders, such as multiple sclerosis, diabe-
tes, and arthritis.21,33–35
The roles of CD8þ T-cell subsets in atherosclerosis remain largely
unexplored, although some studies are suggesting that these cells may
be involved. Tc1 cells have been implicated in atherogenesis, as IFN-c-
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producing CD8þ T cells potentiated atherosclerosis development in
apolipoprotein E-deficient (apoE-/-) mice.36 Additionally, IFN-c produced
by CD8þ T cells was shown to contribute to monopoiesis during early
lesion development in low-density lipoprotein receptor-deficient
(LDLr-/-) mice.37 Moreover, ApoE-/- mice deficient in E3-ligase CBL-B
showed an increase in INF-c and granzyme B-producing CD8þ T cells,
resulting in enhanced macrophage killing and atherosclerosis.38 Finally,
an increase in IL-17-producing CD8þ T cells in the circulation of humans
has been associated with a higher incidence of myocardial infarction,39
hinting at a role for Tc17 cells in cardiovascular disease. However, direct
evidence showing a causal relation between Tc17 cells and atherosclero-
sis is lacking.
Here, we systematically investigated the presence of different CD8þ
T-cell subsets in a murine model of atherosclerosis and observed an in-
crease in the number of Tc17 cells within the lesions. We show that
undifferentiated CD8þ T cells switch to a Tc1 phenotype when trans-
ferred into LDLR-/- mice on a Western-type diet (WTD). CD8þ T cells
that are polarized towards Tc17 cells, however, produced lower levels
of IFN-c upon adoptive transfer and showed to be non-atherogenic. Tc0




C57Bl/6, CD8a-/-, LDLr-/-, and apoE-/- mice were purchased from
Jackson Laboratory (Bar Harbor, Maine, USA) and bred in-house.
CD8a-/- mice were crossed with LDLr-/- mice to obtain CD8a-/-LDLr-/-
mice in-house, after which genotypes were verified by PCR. The mice
were kept under standard laboratory conditions and food and water
were provided ad libitum. For the development of advanced atheroscle-
rotic lesions in apoE-/- mice, mice were kept on a chow diet for 35–
49 weeks before analysis of CD8þ T-cell phenotypes in the lesion. Upon
sacrifice, mice were subcutaneously anaesthetized with a lethal dose of
ketamine (40mg/mL), sedazine (8mg/mL), and atropine (0.1mg/mL). All
animal work were performed in compliance with the Dutch government
guidelines and the Directive 2010/63/EU of the European Parliament.
Experiments were approved by the Ethics Committee for Animal
Experiments of Leiden University.
2.2 Cell preparation and flow cytometry
Mice were sacrificed as described above and blood, spleens, and aortas
were harvested after in situ perfusion with phosphate-buffered saline
(PBS, pH 7.4, Lonza). White blood cells were obtained by lysing blood
samples two times for 2 min with lysis buffer (0.15 M NH4Cl, 1 mM
KHCO3, 0.1 mM Na2EDTA; pH 7.3). Single-cell suspensions of spleens
were obtained by using a 70lm cell strainer (Greiner Bio-One).
Splenocytes were lysed for 1 min with lysis buffer to obtain white blood
cells. Aortas were cleaned of perivascular fat, cut into small pieces, and
digested by incubation with a digestion mix (collagenase I 450 U/mL, col-
lagenase XI 250 U/mL, DNAse 120 U/mL, and hyaluronidase 120 U/mL;
all Sigma–Aldrich) for 30 min at 37C while shaking, and subsequently
strained over a 70lm strainer. Cells were stained with the appropriate
antibodies (Supplementary material online, Table S1). For intracellular
staining, cells were fixed and permeabilized by using an intracellular stain-
ing kit (eBioscience) according to the manufacturer’s protocol. To detect
cytokine production, cells were stimulated for 3.5 h with phorbol 12-
myristate 13-acetate (PMA, 50 ng/mL, Sigma–Aldrich) and ionomycin
(500 ng/mL, Sigma–Aldrich) in the presence of brefeldin A
(ThermoScientific) in complete RPMI 1640 medium containing 25 mM
HEPES (Lonza) supplemented with 5% foetal bovine serum (Greiner),
60lM b-mercaptoethanol (Sigma), 100 U/mL mix of penicillin/strepto-
mycin (Lonza), 1% non-essential amino acids (NEAA; Gibco), 1% sodium
pyruvate (Sigma), and 2% L-glutamine (Lonza) at 37C and 5% CO2.
Flow cytometry analyses were performed on a Beckman Coulter
Cytoflex S and FlowJo software (Treestar).
2.3 In vitro culture of Tc0 and Tc17 cells
Spleens, mesenteric lymph nodes, and iliac lymph nodes were isolated
from C57Bl/6 mice after cervical dislocation. CD8þ T cells were isolated
by using a negative selection magnetic CD8þ T-cell isolation kit (Milteny
Biotec) according to the manufacturer’s protocol. About 0.3 106 cells
were plated per well in a 96-well plate in a total volume of 200lL com-
plete RPMI (as stated above). In order to obtain undifferentiated Tc0
cells, the medium was supplemented with 20 U/mL IL-2 (Peprotech),
0.5 ng/mL IL-7 (Peprotech), 0.5mg/mL soluble anti-CD3
(ThermoScientific), 0.5mg/mL soluble anti-CD28 (ThermoScientific),
and 10mg/mL anti-IFN-c (BioXcell). For Tc17 differentiation, the me-
dium was supplemented with 20 U/mL IL-2 (Peprotech), 0.5 ng/mL IL-7
(Peprotech), 20 ng/mL IL-6 (Peprotech), 5 ng/mL TGF-b (BioLegend),
20 ng/mL IL-1b (Peprotech), 20 ng/mL IL-23 (R&D systems), 0.5mg/mL
soluble anti-CD3 (ThermoScientific), 0.5mg/mL soluble anti-CD28
(ThermoScientific), 10lg/mL anti-IL-4 (BioXcell), and 10mg/mL anti-
IFN-c (BioXcell). The cells were incubated for 2 days at 37C and 5%
CO2, after which the medium was refreshed with the same cytokine
stimulations, but without anti-CD3 and anti-CD28. The cells were incu-
bated for one more day before analysis by flow cytometry or adoptive
transfer.
2.4 RNA isolation and qPCR
RNA was isolated from in vitro-cultured Tc0 and Tc17 cells by phenol/
chloroform extraction. cDNA was synthesized using Maxima H minus
reverse transcriptase reagents (ThermoFisher, Bleiswijk, the
Netherlands) according to the manufacturer’s protocol. After creating
cDNA, the SensiMix SYBR low-ROX kit (GC Biotech, Waddinxveen,
the Netherlands) was used to perform the quantitative PCR (qPCR).
The primers used for the qPCR are listed in Supplementary material on-
line, Table S2. The PCR was run under the following conditions: initial de-
naturation 10 min at 95C, followed by denaturation at 95C for 15 s
and annealing/extension at 64C for 40 s for 40 cycles. The transcription
levels were normalized to the expression of b-actin.
2.5 Adoptive transfer
Blood samples of 100lL were drawn via the tail vein in EDTA-
containing tubes (Sarstedt) from 18 CD8-/-LDLr-/- mice between 8 and
14 weeks of age. Total cholesterol levels were assessed by using an enzy-
matic colorimetric assay (Roche Diagnostics). The mice were random-
ized into two groups based on age, weight, and plasma cholesterol levels.
From the start of the experiment, mice were fed a WTD containing
0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham,
Essex, UK) for 6 weeks. Every week, mice received intravenous injec-
tions of matched numbers of between 8.8 105 and 2.3 106 Tc0 or
Tc17 cells, depending on the amount obtained during isolation (on an av-
erage 1.7 106 per injection). During the experiment, transfer efficiency
was monitored by drawing blood after two and four injections of CD8þ
T cells, 5 days after the mice received the last injection. The mice were







































































































sacrificed using an overdose of anaesthesia (15 mg ketamine, 75 lg atro-
pine, and 3.75 mg xylazine), 1 week after the sixth injection as described
above, and organs were isolated as described under cell preparation and
flow cytometry.
2.6 Histological analysis
All hearts were embedded in optimal cutting temperature com-
pound (Sakura) and horizontally sectioned towards the aortic axis
and the aortic arch. Upon reaching of the aortic root, defined by
the trivalve leaflets, 10lm sections were collected. Lesion size
analysis was performed on cryosections of the aortic root lesion
stained with Oil-red O and haematoxylin (Sigma–Aldrich). Sirius
red staining (Sigma–Aldrich) was performed on corresponding sec-
tions to determine collagen content, and Masson’s Trichrome stain-
ing (Sigma–Aldrich) to determine the necrotic area. Plaque
macrophages were stained immunohistochemically by using a rat
anti-mouse Monocytes/Macrophages antibody (MOMA, 1:1000, AbD
Serotec) as a primary antibody, biotinylated rabbit anti-rat IgG
(1:100; Vector) as a secondary antibody, and Vectastain ABC
horseradish peroxidase in combination with ImmPACT Nova Red
for visualization (Vector). Plaques were stained for VCAM-1 by us-
ing purified rat anti-mouse CD106 (1:100, BD Biosciences) as a
primary antibody, biotinylated rabbit anti-rat IgG (1:200, Vector) as
a secondary antibody, and Vectastain ABC horseradish peroxidase
in combination with Immpact Nova Red for visualization (Vector).
The average plaque size (in lm2) was calculated from five sequen-
tial sections. For all other analyses, three subsequent sections dis-
playing the highest plaque content per mouse were analysed. All
microscopic analyses were performed on a Leica DM-RE micro-
scope using Leica QWin software and were blinded for indepen-
dent analysis. The relative amount of collagen, macrophages, and
necrosis in the atherosclerotic lesions was quantified by dividing
the area stained positive for collagen, MOMA or that displaying ne-
crosis by the total lesion surface area, and calculated as a
percentage.
2.7 Statistical analysis
The data are presented as individual dot plots with bars denoting the
mean, and the number of animals in each group is stated in the text. Data
were tested for normal distribution by using a Shapiro–Wilk normality
test and analysed by using a two-tailed Student’s t-test, Mann–Whitney
test, one-way or two-way ANOVA, as appropriate. Statistical analysis
was performed using Prism (GraphPad). Probability values of P < 0.05
were considered significant.
3. Results
3.1 Increased expression of RORct by
CD8þ T cells derived from advanced
murine atherosclerotic lesions
We investigated the presence of the different CD8þ T-cell subsets in
the atherosclerotic lesions of apoE-/- mice with advanced atheroscle-
rosis using flow cytometry. We focused on the difference in pheno-
type between CD8þ T cells derived from the aortic lesions and their
counterparts in the spleen, as these cells can locally affect the lesion
development and composition. We observed a significant decrease in
the percentage of CD8þ T cells that produce IFN-c within the
lesions compared to their counterparts in the spleen (11.7% vs.
39.3%, Figure 1A, representative FACS plots in Supplementary mate-
rial online, Figure S1). This is in line with our previous research,
showing a reduced number of cytokine-producing CD8þ T cells in
the lesions of these mice, probably due to the immunosuppressive
effects of increased CD39-expression on these cells.40 We were un-
able to detect any IL-4 secretion by aortic CD8þ T cells, whereas
we did detect low levels of this cytokine in the splenic CD8þ T cells
(Figure 1B). Conversely, we observed no production of IL-5 by
splenic CD8þ T cells, whereas there was a low expression of this cy-
tokine in their aortic counterparts (Figure 1C). Finally, we observed
only very low expression levels of IL-17A in the CD8þ T cells de-
rived from both sites, with no significant differences between the dif-
ferent sites (Figure 1D) and no production of IL-10 was detected
(Figure 1E). Due to the low cytokines levels, we looked into the ex-
pression of the key transcription factors associated with the different
Tc subsets in the lesions of these mice: T-bet, GATA3, RORct, and
FOXP3 for Tc1, Tc2, Tc17, and regulatory CD8þ T cells (TcReg), re-
spectively. Interestingly, we observed a significant 45-fold increase in
the percentage of CD8þ T cells that are positive for RORct
(Figure 1G), as well as a 19-fold increase in the percentage of
GATA3-expressing CD8þ T cells (Figure 1F) and an almost two-fold
increase in FOXP3 positive CD8þ T cells in the aorta compared to
the spleen (Figure 1H), whereas the percentage of T-bet-expressing
CD8þ T cells showed a three-fold decrease (Figure 1E). Of note, we
only observed IFN-c production by the T-bet positive CD8þ T cells
in the aorta, but not by the RORct or GATA3-expressing CD8þ T
cells (Supplementary material online, Figure S1), confirming function-
ally distinct lineages. As there was such a pronounced increase in the
RORct-expressing lesional CD8þ T cells, we set out to further ex-
plore the role of Tc17 cells in atherosclerosis.
3.2 In vitro characterization of Tc0 and
Tc17 cells
To evaluate the role of Tc17 cells in atherosclerotic lesion develop-
ment, we decided to perform an adoptive transfer of Tc17 cells into
LDLr-/- CD8-/- mice. First, we cultured undifferentiated CD8 T cells
(Tc0) and Tc17 cells in vitro, based on previously published proto-
cols.33,41,42 CD8þ T cells were isolated from wild-type mice and acti-
vated by using anti-CD3 and anti-CD28 antibodies. Tc0 were
cultured for 3 days in medium supplemented with IL-2, IL-7, and
anti-IFN-c. Tc17 cells were differentiated for 3 days in medium sup-
plemented with IL-2, IL-7, IL-6, IL-1b, TGF-b, IL-23, anti-IL-4, and
anti-IFN-c. Flow cytometry analysis revealed that our approach led
to a robust Tc17 phenotype, with a 19-fold increase in the percent-
age of cells positive for IL-17A in the Tc17 cells compared to the
Tc0 cells (24.8% vs. 1.3%, Figure 2A, representative FACS plots shown
in Supplementary material online, Figure S2), associated with a five-
fold increase in RORct-expressing cells (13.2% vs. 2.7%, Figure 2B),
and a reduction in T-bet-expressing cells (7.3% vs. 25.1%, Figure 2D).
Moreover, both Tc0 and Tc17 produced low amounts of IFN-c
(4.5% and 4.9%, respectively, Figure 2C), indicating that these cells do
not display a Tc1 phenotype. We observed a low production of IL-5
by both subsets, although the Tc0 subset produced three-fold more
IL-5 compared to the Tc17 subset (2.4% vs. 0.8%, Figure 2E). The
percentage of GATA3þ cells was low in both groups and did not dif-
fer between the two subsets (Figure 2F), indicating the cultured cells
do not display a Tc2 phenotype. Finally, we confirmed the Tc17


















































.phenotype on transcriptional level and show increased expression of
RORyt and CCR6, another established Th17 marker (Supplementary
material online, Figure S3).
3.3 Adoptively transferred CD8þ T cells
migrate to the atherosclerotic lesion and
affect the local CD4þ T-cell population
To determine the effect of Tc17 cells on the development of atheroscle-
rosis, in vitro cultured Tc0 or Tc17 cells were adoptively transferred into
LDLr-/- mice that were also deficient in CD8 (CD8-/-LDLr-/- mice) and
therefore had no endogenous CD8þ T-cell population (Supplementary
material online, Figure S4A, overview of experimental setup:
Supplementary material online, Figure S4B). Besides the absence of
CD8þ T cells in these mice, the composition of blood leucocytes in
CD8-/-LDLr-/- mice was comparable to that of LDLr-/- mice
(Supplementary material online, Figure S5A), with only minor changes in
monocyte activation (Supplementary material online, Figure S5B).
Deletion of CD8a may also result in the ablation of CD8þ dendritic cells
(DCs). Although, CD8þ DCs have a dominant role in antigen cross-pre-
sentation,43 DCs from CD8-/-LDLr-/- were able to induce CD8þ T-cell
expansion to a similar extend as DCs from LDLr-/- mice, after exposure
to ovalbumin in vivo and in vitro (Supplementary material online, Figure
S5C and D). This suggests cross-presentation in CD8-/-LDLr-/- mice is
not impaired. In line with reports in CD8-deficient apoE-/- mice,44,45
atherosclerotic lesion development was not affected by ablation of
CD8þ T cells, as atherosclerotic lesions were comparable in size and
composition after feeding LDLr-/- mice and CD8-/-LDLr-/- mice (age 8–
15 weeks) a WTD for 6 weeks (Supplementary material online, Figure
S5E–G).
The adoptive transfer with in vitro expanded Tc0 (control group) or
Tc17 (treatment group) cells resulted in an increase in the CD8þ T-cell
population in the blood of both treatment groups over time (Figure 3A).
At 4 weeks post the first adoptive transfer, the circulating CD8þ T cells
in the Tc17-treated group showed a substantially (four-fold) increased
production of IL-17A compared to those in the Tc0-treated group (6.4%
vs. 1.7%, Figure 3B), suggesting a stable Tc17 phenotype. Interestingly, we
observed plasticity in the Tc0 subset, as these cells showed an increase
in IFN-c production from 4.5% at baseline to 53.6% 4 weeks after the
first transfer. The Tc17 cells also showed an increased IFN-c production
from 4.9% to 44.9% (Figures 2C and3C). Therefore, we analysed the rela-
tive amount of splenic IFN-cþCD8þ T cells at sacrifice. Again, we ob-
served that in the Tc0-treated group a larger fraction of the cells
produce IFN-c (75.9%) compared to those in the Tc17-treated group
(30.5%, Figure 4A and C), although in both groups, the percentage of IFN-
cþ cells was notably higher than directly after in vitro differentiation
(Figure 2C). In line with our expectations, the Tc17-treated group still dis-
played more IL-17Aþ cells as compared to the Tc0 group (7.6% vs. 2.2%,
Figure 4B and C), albeit less compared to the in vitro cytokine production
levels at the moment of injection (Figure 2A). Moreover, at sacrifice,
Figure 1 Murine atherosclerotic lesions display an increased expression of the Tc17-associated transcription factor RORct as well as the Tc2-associ-
ated transcription factor GATA3 within the CD8þ T-cell compartment compared to the spleen. Flow cytometric analysis of IFN-cþ (A), IL-4þ (B), IL-5þ
(C), IL-17Aþ (D), IL-10þ(E), T-betþ (F), GATA3þ (G), RORctþ (H), and FOXP3 (I) CD8þ T cells in the aortas and spleens of apoE-/- mice stimulated for
3.5h with PMA and ionomycin. Cells were pre-gated on live, Thy1.2þCD8þ T cells. Representative FACS plots are available in Supplementary material
online, Figure S1. Individual data points and mean±SEM of n=5 (A, B, F), n=4 (C, D, G, H), or n = 4 vs. 3 (E, I) apoE-/- mice of 35–49 weeks old, data are rep-
resentative of n = 3 independent experiments. Significance was determined by using an unpaired t-test (A, C) or a Mann–Whitney test (B, D, E, F, G, H, I).
*P < 0.05, **P < 0.01, ***P < 0.001.











































..86.1% of CD8þ T cells in the Tc0 group expressed T-bet, whereas in the
Tc17 group this comprised 46.1% of the total CD8þ population (Figure
4D and F), suggesting the majority of the injected Tc0 cells had converted
to a Tc1 phenotype. We observed a non-significant 1.2-fold increase in
RORct expression in the Tc17-treated group compared to the controls
(Figure 4E and F). Of note, the adoptively transferred CD8þ T cells were
able to proliferate in vivo, as we observed 30.2% and 20.0% Ki-67 expres-
sion in the Tc0 and Tc17 groups, respectively (Figure 4G and I). No differ-
ences were observed in the percentage of FoxP3þCD8þ T cells
between the different groups (Supplementary material online, Figure
S4C).
Besides the spleen and blood, we were able to detect CD8þ T cells in
the aortic lesions of both Tc0- and Tc17-recipient mice at the time of
sacrifice (Figure 4H), illustrating that the adoptively transferred CD8þ T
cells migrate into the plaques. However, as the total number of lympho-
cytes within murine aortas is low, these numbers did not allow us to dis-
tinguish the different CD8þ T-cell subsets. Interestingly, we did observe
changes in the CD4þ T-cell compartment in the lesion, showing a signifi-
cant increase in IFN-c production (Figure 4J and L, P < 0.05) and T-bet
expression (Figure 4K and L, P < 0.05) in the Tc0-treated group,
suggesting a skewing towards an inflammatory Th1 phenotype. This Th1
skewing effect was minimal and not statistically different after Tc17 trans-
fer (Figure 4J–L).
3.4 Adoptive transfer of Tc17 cells does not
accelerate atherosclerotic lesion
development in CD8-deficient atheroscle-
rotic mice
We next assessed how the adoptive transfer of CD8þ T cells affects ath-
erosclerosis development. The weight of the mice was unaffected,
whereas cholesterol levels in serum were significantly increased by
CD8þ T-cell transfer of both Tc0 as well as Tc17 cells (Supplementary
material online, Figure S4D and E). Plaque size was assessed in the aortic
root lesions of the hearts. Interestingly, neutral lipid staining of the
lesions revealed that the average lesion size of Tc17-transferred CD8 T
cells was equal to CD8-/-LDLr-/- mice that did not receive a transfer
(Figure 5A). However, Tc0 mice that received the adoptively transferred
Tc0 cells showed a 57.6% increase in lesion size, compared to the Tc17-
treated group (Figure 5A). The increase in lesion size in the Tc0-treated
Figure 2 Tc0 and Tc17 cells demonstrate phenotypical differences in cytokine production and transcription factor expression. Flow cytometric analy-
sis of IL-17Aþ (A), RORctþ (B), IFN-cþ (C), T-betþ (D), IL-5þ (E), and GATA3þ (F). CD8þ T cells isolated from C57Bl/6 mice and polarized for 3 days to-
wards Tc0 or Tc17 cells. Cells were stimulated for 3.5h with PMA and ionomycin and pre-gated on live, Thy1.2þCD8þ T cells. Representative FACS
plots are available in Supplementary material online, Figure S2. Individual data points and mean±SEM of n=3, Representative of three independent experi-
ments. Significance was determined by using an unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001.
































































..group is partially due to an elevation in total macrophage accumulation,
as MOMA positive are increased 2.8-fold, although this did not reach sta-
tistical significance. The relative plaque composition appeared to be simi-
lar in the Tc17- and Tc0-treated groups, as no change in the percentage
of MOMA positive, necrotic area, or collagen positive area was observed
(Figure 5B–D). Analysis of the VCAM-1þ area in the caps of the lesion
revealed a 1.5-fold increase in the Tc0-treated group, although this did
not reach significance (P = 0.21, Supplementary material online, Figure
S6A and B).
4. Discussion
CD8þ T cells play an important role in the adaptive immune response,
responding to intracellular pathogens. Recently, CD8þ T-cell subsets
such as Tc1, Tc2, and Tc17, which are characterized by their cytokine
production resulting from different environmental cues, have been
reported to also play a role in various autoimmune disorders.21 We re-
port a large increase in Tc17 cells in the atherosclerotic lesion microen-
vironment specifically and show that adoptively transferred Tc17 cells
do not contribute to the progression of atherosclerosis, while athero-
sclerotic lesion development was enhanced in Tc0-treated mice.
It is of particular interest to investigate the phenotype and function of
CD8þ T cells within the lesion, as we have previously reported that
CD8þ T cells can locally affect the lesion development and composi-
tion.46 However, it is difficult to determine the presence of the different
CD8þ T-cell subsets within the lesional microenvironment based on
their cytokine production, as the production of inflammatory cytokines
produced by CD8þ T cells within the lesions is reduced.40 Indeed, here
we report a reduced percentage of IFN-cþ lesion-derived CD8þ T cells
compared to their counterparts in the spleen and were hardly able to
detect any IL-4, IL-5, or IL-17A production above background levels in
the aorta of old apoE-/- mice. Therefore, we set out to measure the tran-
scription factors associated with the Tc1, Tc2, and Tc17 subsets instead.
There is a reduced percentage of CD8þ T cells expressing T-bet in aor-
tic lesions compared to splenic CD8þ T cells, suggesting that the pro-
inflammatory Tc1 subset is not enriched in the lesion environment.
However, we observed a modest increase in the percentage of cells
expressing GATA3 in the lesions, implying an increase in Tc2 cells com-
pared to lymphoid tissues. Strikingly, the percentage of cells expressing
RORct was strongly increased within the lesion microenvironment,
which indicates a relative enrichment of Tc17 cells at the site of disease.
It has previously been reported that 3 months of high-fat diet feeding in
apoE-/- mice results in increased IL-17A production by splenic T cells,47
although the cell type responsible for this increase was not specifically
identified. We observed only very low percentages of IL-17þCD8þ T
cells in the spleens of apoE-/- mice, which were kept on a chow diet.
Nonetheless, this study suggests that the inflammatory stimuli associated
with the development of atherosclerosis may drive Tc17 skewing.
Moreover, another analysis of the entire T-cell compartment showed an
increase in IL-17A production in the aorta compared to the spleens of
apoE-/- mice fed a WTD for 15 weeks.16 As there are enhanced levels of
the Tc17-polarizing cytokines IL-1b and IL-6 in the plaque,48,49 the ath-
erosclerotic environment in the lesion may indeed drive the local T cells
to differentiate towards a Tc17 phenotype, or stimulate increased re-
cruitment of these cells.
In vitro polarization of isolated CD8þ T cells from wild-type mice
resulted in successful differentiation towards a Tc17 phenotype, as de-
scribed previously using a similar differentiation protocol.41 Some basal
levels of IFN-c were produced by both the Tc0 and Tc17 cells, which is
in agreement with available data.33,41 There was an increased expression
of T-bet in the Tc0 subset compared to the Tc17 subset, which we hy-
pothesize is due to the natural tendency of CD8þ T cells to differentiate
towards an inflammatory effector phenotype upon the addition of IL-2,
anti-CD3, and anti-CD28 antibodies.50 Indeed, we found that the addi-
tion of anti-IFN-c to the Tc0 conditions induced a great reduction in the
T-bet expression, strengthening this hypothesis. However, upon adop-
tive transfer, Tc0 cells up-regulated their expression of T-bet and IFN-c
Figure 3 CD8þ T-cell populations increase over time upon adoptive transfer in both treatment groups. (A) Analysis of percentages of CD8þ T cells in
the blood of the CD8-/-LDLr-/- mice after two and four injections of Tc0 or Tc17 cells and at sacrifice. Cells were pre-gated on live, Thy1.2þ cells,
mean±SEM. (B) IL-17A and (C) IFN-c production by the CD8þ T cells in the blood after four injections, as analysed by flow cytometry. Cells were stimu-
lated for 3.5h with PMA and ionomycin and pre-gated on live, Thy1.2þCD8þ T cells. Individual data points and mean±SEM, n = 9 mice per group, mice
that did not show detectable numbers of CD8þ T cells were not included in the analysis of panels (B) and (C). Significance was determined by using a
two-way ANOVA with Bonferroni’s multiple comparisons (A) or by using an unpaired t-test (B and C). **P < 0.01.
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Figure 4 Adoptive transfer of Tc17 cells in CD8-/-LDLr-/- mice skews the CD4þ T cells towards a less inflammatory phenotype in the aortic microenvi-
ronment. Flow cytometric analysis of IFN-cþ (A), IL-17Aþ (B) T-betþ (D) RORctþ (E), and Ki-67þ (G) CD8þ T cells in the spleens of the CD8-/-LDLr-/-
mice that received the adoptive transfer of Tc0 or Tc17 cells at the time of sacrifice. Representative FACS plots are shown in (C, F, I), cytokine-positive
populations were gated based on unstimulated controls. Cells were pre-gated on live, Thy1.2þCD8þ T cells. (H) percentages of CD8þ T cells in the aor-
tas of the CD8-/-LDLr-/- mice at the time of sacrifice, analysed by flow cytometry. Cells were pre-gated on live, Thy1.2þ cells. Flow cytometry analysis of
IFN-cþ (J) and T-betþ (K) CD4þ T cells in the aortas of the CD8-/-LDLr-/- mice at the time of sacrifice. Representative FACS plots are shown in (L), cyto-
kine-positive populations were gated based on unstimulated controls. Cells were pre-gated on live, Thy1.2þCD4þ T cells. Cells were stimulated for 3.5h
with PMA and ionomycin. Individual data points and mean±SEM, n = 9 mice per group. Significance was determined by using a Mann–Whitney test (A, B,
D, G) or by using an unpaired t-test (C, E, F, H, I). *P < 0.05, **P < 0.01, ***P < 0.001.





































production, indicating a switch towards the Tc1 phenotype. The Tc17
cells retained IL-17A production in vivo, though at lower levels than after
in vitro differentiation. Finally, the RORct expression was down-regulated
in these cells. Indeed, previous work using antigen-specific Tc17 cells has
shown that these cells can convert to IFN-c-producing cells, although
they retain some of their IL-17A production.41 Similar plasticity has been
reported for CD4þ Th17 subsets.51,52 To date, the molecular mecha-
nisms underlying these switches in phenotype remain unknown.
However, the pro-inflammatory environment in the atherosclerotic
mouse model may contribute to the increased production of IFN-c, as
hypercholesterolaemia results in increased inflammatory responses.53,54
As CD8þ T cells activated by using anti-CD3 and CD28 antibodies tend
to differentiate towards an effector phenotype,50,55 it is likely that ab-
sence of anti-IFN-c, that was present in vitro, as well as the inflammatory
signalling induced by the WTD-feeding in our mouse model, drives the
switch towards a Tc1 phenotype. Indeed, the Tc0 cells showed a similar
phenotype in vivo to that which we observed for the splenic CD8þ T
cells in the atherosclerotic apoE-/- mice. Tc17 cells continued to produce
IL-17A, but also gained the ability to produce IFN-c. This may be
explained by different transcriptional programs that are at work within
this subset. IL-12, a cytokine known to be up-regulated in atherosclerotic
mice,56 is able to induce repressive epigenetic modification of the
SOCS3 promoter. As SOCS3 is an essential mediator of IL-17 produc-
tion, increased IL-12 levels in the blood can stimulate the conversion of
Tc17 cells towards a mixed Tc1/Tc17 phenotype, associated with an in-
creased IFN-c production.57 This is in agreement with our work, in
which we observed maintenance of the Tc17 cytokine profile, but addi-
tional acquired characteristics of Tc1 cells. Previous work has demon-
strated reciprocal plasticity between CD4þ Th17 and Treg cells, since
Th17 polarized cells can differentiate into Tregs in vivo and vice versa.58
Figure 5 Adoptive transfer of Tc17 cells does not affect atherosclerotic lesion size, nor plaque composition, while a transfer of Tc0 cells accelerates le-
sion formation. (A) Quantification of lesion size in the aortic roots by Oil-red O staining and representative pictures of the trivalve area of CD8-/-LDLr-/
-mice treated with Tc0 or Tc17 cells and the no-treatment group. (B) Quantification of relative monocyte/macrophage content in the aortic root lesions
by MOMA staining and representative pictures of the lesions. (C) Quantification of relative necrotic core area and (D) relative collagen content in the aor-
tic root lesions by Masson’s Trichrome staining and representative pictures of the lesions. Individual data points and mean±SEM, n=8 or 9 mice per group.
Significance was determined by using an unpaired t-test. Outliers were removed after a Grubbs’ test. *P < 0.05, **P < 0.01, ***P < 0.001.







































































































From this, it could be suggested that Tc17 cells can differentiate into reg-
ulatory CD8þ T cells via similar transcriptional mechanisms in our
model. However, we observed no differences in FoxP3-expressing
CD8þ T cells in our studies.
Of note, the Tc0 cells were more proliferative than their Tc17 counter-
parts. Possibly, the Tc0 cells resemble a more naı̈ve phenotype as they are
less fixed in their transcriptional program towards a certain phenotype.
This enables them to proliferate more vigorously upon antigen recogni-
tion in vivo, compared to their more differentiated counterparts.59
The injected CD8þ T cells were able to infiltrate the lesions in vivo,
supporting the notion that local CD8þ T-cell interactions in the lesions
may have contributed to the observed differences between the Tc17-
and Tc0-treated groups. However, we were unable to establish differen-
ces between the different treatment groups in expression of transcrip-
tion factors or the production of cytokines by these aortic CD8þ T cells,
as the cell numbers were too low to draw any significant conclusions
about subsets within the population. Interestingly, no change in plaque
size or composition could be identified between the Tc17-treated group
and non-treated CD8-/-LDLr-/- mice, whereas transfer of Tc0 cells signifi-
cantly increased the size of atherosclerotic lesions. This strongly suggests
Tc17 are not atherogenic and their enrichment in the plaques of CD8
competent mice does not drive plaque progression and instability.
Previous reports have shown an atheroprotective effect of IL-17, as in-
creased expression of IL-17 reduced lesion development and neutraliza-
tion of IL-17 accelerated atherosclerosis.18 The proposed
atheroprotective effect of IL-17 might contribute to the reduced patho-
genicity of Tc17 cells. Alternatively, the reduced levels of IFN-c pro-
duced by Tc17 may also account for this. IFN-c is able to augment
macrophage activation,60 which may, in turn, contribute to increased
atherosclerosis development. IFN-c-/-apoE-/- mice have been shown to
display a large reduction in atherosclerosis compared to controls, associ-
ated with a decrease in lesion cellularity but an increase in lesional colla-
gen content.36 In another study, administration of IFN-c to apoE-/- mice
resulted in a two-fold increase in lesion size, mediated by an increase in
both T cells as well as APCs.61 CD8þ T-cell-derived IFN-c has previously
been shown to have limited impact on lesion size and stability,62 but this
study was performed in lymphocyte-deficient apoE-/- mice, which may
overlook the effect of CD8þ T-cell-derived IFN-c on CD4þ T cells. We
observed an increase in the total macrophage content of the lesions in
the Tc0 group compared to the Tc17 and no transfer group, which could
be mediated by the increased IFN-c that is produced in these mice. In
fact, we observed an increase in T-bet expressing Th1 CD4þ T cells in
the lesion microenvironment of the Tc0-treated mice. IFN-c is an impor-
tant regulator of T-bet expression within CD4þ T cells,63–65 suggesting
that the increase in Th1 cell population within the lesions of the Tc0-
treated mice could be due to the increase in IFN-c levels. In addition to
the inflammatory effects of the adoptively transferred cells, this increase
in the Th1 cell population within the lesions further promotes inflamma-
tion and atherogenesis, as these cells also display atherogenic functions.6
Thus, both the percentual increase in IL-17A as well as the percentual
decrease in IFN-c production by the Tc17 cells compared to the Tc0
cells may have contributed to the reduce pathogenic effects observed
here.
5. Conclusion
In conclusion, we have shown an enrichment in Tc17 cells in the plaque
microenvironment of atherosclerotic mice. The enrichment of Tc17
cells does not affect the progression of atherosclerosis, in contrast to
their Tc0 counterpart. These findings demonstrate the presence of dif-
ferent Tc subsets within atherosclerotic lesions and warrant further re-
search to the function of these subsets in the plaque microenvironment.
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Translational perspective
CD8þ T cells are present in high numbers in human atherosclerotic plaques, however, their role in inflammation and the pathogenesis of atheroscle-
rosis remains elusive. Our results indicate that the majority of CD8þ T cells in atherosclerotic plaques of mice has lost their ability to produce the
pro-inflammatory cytokine IFN-c and gain traits of IL-17-producing CD8þ T cells (Tc17 cells). We show that this subset of CD8þ T cells is less ath-
erogenic then IFN-c producing Tc1 cells.
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